Sviluppo di nuovi approcci farmacologici per indurre la morte cellulare in una linea di micosi fungoide

Mycosis fungoides (MF) is the most common form of primary cutaneous T-cell lymphoma (CTCL) and represents about 50% of all primary cutaneous lymphomas (PCL). Although the initial stages of MF present an indolent clinical course and can benefit from “skin-directed” treatment, patients who relapse or are resistant to treatment are destined to progress to the advanced stages of the cancer. These latter are considered incurable and available treatments are mostly palliative in nature. Unlike normal cells, cancer cells present high levels of ROS. The use of compounds capable of increasing the amount of ROS inside cancer cells to bring them to cytotoxic levels may be an effective therapeutic strategy to selectively target the mutant cells.